InterCure Ltd. Share Price TEL AVIV STOCK EXCHANGE

INCR

IL0011063760

Healthcare Facilities & Services

News in other languages : InterCure Ltd.

02/01/20

Tilray, Inc. : première exportation de cannabis vers Israël

More news

Managers and Directors : InterCure Ltd.

Manager	Title	Age	Since
Alexander Rabinovitch CEO	Chief Executive Officer	55	23/12/2019
Amos Cohen DFI	Director of Finance/CFO	47	29/02/2020
Itai Kabiljo LAW	General Counsel	-	31/03/2022

Director	Title	Age	Since
Lennie Michelson Grinbaum BRD	Director/Board Member	50	02/09/2015
David Salton BRD	Director/Board Member	66	13/12/2014
Alexander Rabinovitch CHM	Chairman	55	12/02/2025

More insiders

InterCure Ltd. is an Israel-based company engaged in the medical cannabis industry. Through its wholly owned subsidiary, Canndoc Ltd., the Company cultivates, produces, processes, markets, and distributes medical cannabis products. Its operations include the development and manufacture of pharmaceutical-grade medical cannabis products produced in accordance with Good Manufacturing Practice (GMP) standards. The Company offers a range of cannabis-based products for medical use and operates across various stages of the medical cannabis value chain, including cultivation, manufacturing, logistics, distribution, and retail activities. In addition, the Company is involved in the import, export, and commercialization of medical cannabis products and related healthcare solutions in Israel and selected international markets.

Employees

Sector

Healthcare Facilities & Services

More about the company

Market Cap	197M 592M 170M 159M 146M 272M 18.6B 273M 1.88B 731M 9.53B 739M 723M 30.76B	P/E 2024	-4.01x	P/E 2025	-4.87x
Enterprise Value	333M 1B 287M 270M 246M 461M 31.48B 463M 3.19B 1.24B 16.14B 1.25B 1.22B 52.05B	EV / Sales 2024	1.69x	EV / Sales 2025	1.16x
Free-Float	60.83%	Yield 2024 *	-	Yield 2025	-

08-24	InterCure Ltd. announced that it has received ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
08-24	Intercure Ltd. Finalizes Settlement for War-Related Indirect Damages with the Israeli Tax Authorities and Compensation Fund the Subsequent War	CI
06-22	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
06-15	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT
06-14	InterCure Ltd. acquired 50% stake of Botanico Ltd.	CI
06-14	InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd.	CI
04-30	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	InterCure Receives Noncompliance Notice From Nasdaq	MT
03-03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE
02-19	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million	RE
12-18	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court	RE
11-03	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.	CI
11-03	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd	CI

08-24	InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages	AQ
08-19	InterCure Ltd. Announces 1-for-5 Reverse Share Split	AQ
06-22	InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds	AQ
06-15	InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition	AQ
04-30	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERCURE LTD.	+0.22%	-0.51%	-	-	63.9M
VILLAGE FARMS INTERNATIONAL, INC.	+0.86%	+2.10%	+13.18%	+227.35%	354M
ORGANIGRAM GLOBAL INC.	+0.63%	-5.36%	-28.05%	-22.82%	161M
CANNARA BIOTECH INC.	+0.51%	-0.50%	+16.37%	+99.00%	142M
ASCEND WELLNESS HOLDINGS, INC.	+5.68%	+10.71%	-30.60%	-39.61%	89.41M
INTERCURE LTD.	+2.47%	-2.86%	-39.07%	-43.35%	63.9M
IANTHUS CAPITAL HOLDINGS, INC.	0.00%	0.00%	0.00%	-80.00%	25.29M
Average	+1.48%	-1.43%	-11.36%	+23.43%	139.3M
Weighted average by Cap.	+1.29%	-0.95%	-3.31%	+98.73%

	2024	2025
Net sales	239M 719M 206M 193M 177M 330M 22.57B 332M 2.28B 887M 11.57B 897M 877M 37.31B	270M 813M 233M 219M 200M 374M 25.53B 375M 2.58B 1B 13.09B 1.01B 992M 42.21B
Net income	-67.8M -204M -58.38M -54.85M -50.14M -93.81M -6.41B -94.13M -648M -252M -3.28B -255M -249M -10.59B	-35.71M -107M -30.75M -28.89M -26.41M -49.41M -3.37B -49.58M -342M -133M -1.73B -134M -131M -5.58B
Net Debt	133M 400M 114M 107M 98.18M 184M 12.54B 184M 1.27B 493M 6.43B 498M 488M 20.74B	136M 410M 117M 110M 101M 189M 12.88B 189M 1.3B 506M 6.6B 512M 501M 21.3B

InterCure Ltd. Share Price TEL AVIV STOCK EXCHANGE

Stocks

INCR

IL0011063760

Healthcare Facilities & Services

Valuation : InterCure Ltd.

Latest news : InterCure Ltd.

Press Releases : InterCure Ltd.

News in other languages : InterCure Ltd.

Quotes and Performance

Managers and Directors : InterCure Ltd.

Medical Farming

Financials

Company Profile